Description: Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Home Page: www.fatetherapeutics.com
12278 Scripps Summit Drive
San Diego,
CA
92131
United States
Phone:
858 875 1800
Officers
| Name | Title |
|---|---|
| Mr. J. Scott Wolchko | Founder, CEO, CFO, President, Principal Financial & Accounting Officer and Director |
| Ms. Cindy R. Tahl J.D. | Chief Legal & Compliance Officer and Corporate Secretary |
| Dr. Bahram Valamehr M.B.A., Ph.D. | President of Research & Development |
| Dr. Jerome Bressi Ph.D. | Chief Regulatory & Quality Officer |
| Mr. Andrew Henry | Senior Vice President of Clinical Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.74 |
| Price-to-Sales TTM: | 19.1763 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 181 |